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IGFBP7 of BRAF-mutated melanoma
cells triggered their apoptosis both
in vitro and in vivo in a xenotrans-
plantation model. Similarly, reacti-
vation of IGFBP7 by DNA demethy-
lation inhibits colon cancer cell growth
in vitro (Lin et al., 2008). With this
therapeutic implication in mind, we
further scrutinized the expression of
IGFBP7 in melanoma. To this end, we
stained formalin-fixed tissues obtained
from 41 primary tumors and 16 metas-
tases for IGFBP7 expression. Unlike
Wajapeyee and colleagues, however,
we did not detect a clear demarcation
of IGFBP7 expression between BRAF wt
(wild type) and mutated melanoma
lesions (Figure 1). Indeed, although the
frequency of IGFBP7-expressing cells
is lower in BRAF-mutated melanoma
lesions overall, the whole diversity of
IGFBP7 expression from absent to
present in 100% of tumor cells was
observed in both wt and BRAF-mutated
lesions (P¼0.1609; Mann–Whitney
test). Accordingly, western blot analysis
of short- and long-term cultured
melanoma cell lines did not show any
correlation between IGFBP7 protein
expression and BRAF status either
(Figure 2). Heterogeneous IGFBP7 ex-
pression could still be in accordance
with the reported stringent IGFBP7/
BRAF correlation, assuming a corre-
sponding heterogeneity in the BRAF
status. However, the homogeneous
IGFBP7 expression in some of the
BRAF-mutated tumors, as well as the
lack of correlation for the cell lines,
with one of them being hemizygote for
the V600E BRAF mutation, argues
against an obligatory downregulation
of IGFBP7 expression in BRAF-mutated
melanoma cells. Rather, it seems that
loss of IGFBP7 expression is not the
only way to overcome MAPK
pathway–induced senescence. In this
regard, dysregulation of the other
16 candidates detected by Wajapeyee
et al. (2008), including BNIP3L, FOXA,
and NF2, may be alternative mediators
for overcoming senescence. Thus, de-
tailed studies scrutinizing different
modi operandi by which melanoma
cells overcome BRAF-induced senes-
cence are needed before the potential
of IGFBP7 substitution for treatment of
melanoma can be estimated.
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TO THE EDITOR
Dendritic cells (DCs) have crucial roles
in driving primary immune responses
toward immunity or tolerance. While
immature DCs prompt tolerance in
peripheral tissues, mature DCs drive
immunity in lymph nodes (Banchereau
et al., 2000). A particular subset
of DC, however, is thought to have
the ability to induce tolerance regard-
less of the maturation state (Gilliet and
Liu, 2002).
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Figure 2. Lack of correlation between NRAS/BRAF mutational status and IGFBP7 expression in
melanoma cell lines. The NRAS/BRAF status of cell lines was determined by sequencing. Lysates from
these short- and long-term cultured melanoma cell lines were subsequently evaluated using western blot
analysis for IGFBP7 expression.
Abbreviations: DC, dendritic cell; IDO, indoleamine 2,3-dioxygenase; pDC, plasmacytoid DC; SLN,
sentinel lymph node; TLR, toll-like receptor
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Munn et al. (2002) have described a
subset of CD123þ /CCR6þ DC in sen-
tinel lymph nodes (SLN) of cancer
patients with regulatory function.
These cells express high levels of
indoleamine 2,3-dioxygenase (IDO),
the tryptophan-catabolizing enzyme,
which is emerging as a master regulator
of tolerance (Munn et al., 1998; Liu
et al., 2006).
Indoleamine 2,3-dioxygenaseþ cells
are present in SLN of patients with
melanoma, breast, colon, lung, and
pancreatic cancer (Munn and Mellor,
2007). A high number of IDOþ cells
occur in 45% of melanoma SLN,
with or without metastasis. Importantly,
this accumulation correlates with poor
outcome (Lee et al., 2003) strongly
suggesting a tolerance role for
IDOþ cells. They are located in perisi-
nusoidal regions of nodes, surrounding
high endothelial venules; they exhibit
monocytoid or plasmacytoid morphol-
ogy and, in metastatic SLN, form
clusters around melanoma nests. There-
fore, IDO expression seems to be a
crucial, tolerogenic mechanism in can-
cer immunity (Munn and Mellor, 2007).
Consistently, IDO overexpression in
tumor cells protects them from im-
mune-mediated rejection, whereas
the IDO inhibitor 1-methyl tryptophan
can revert to tumor immune tolerance
(Muller et al., 2005; Hou et al.,
2007).
Plasmacytoid DCs (pDCs) are the
main source of the antiviral/antitumor
Type I IFN (Siegal et al., 1999; Liu,
2001). Paradoxically, in vitro studies
show an active role of pDC in tolerance
induction (Gilliet and Liu, 2002; Ito
et al., 2007). Whether they have any
role in cancer immunology has not
been established. Yet, pDC, identified
by the expression of the specific marker
BDCA2 (Dzionek et al., 2001), are
present in SLN, with high frequency in
those bearing metastasis (Gerlini et al.,
2007). Evidence that these pDC show
an inactive immunophenotype and do
not produce IFN-a hints that they favor
tumor tolerance in humans (Gerlini
et al., 2007). In keeping with a role
for both pDC and IDO in suppression of
tumor immunity, IDO is expressed by a
subset of mouse pDC in melanoma
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Figure 1. Sentinel lymph node (SLN) BDCA2þ plasmacytoid dendritic cells (pDCs) express indoleamine 2,3-dioxygenase (IDO). Immunofluorescence
analyses of pDC in human melanoma SLN (n¼ 15: 4 positive for metastasis and 11 negative). Labeling was performed with mouse anti-human BDCA2, to
identify pDC (revealed with goat anti-mouse Alexa Fluor 594 conjugated; red) and with rabbit anti-human IDO (revealed with goat anti-rabbit FITC conjugated;
green). Nuclei were labeled with Hoechst 33342 (blue). (a) Immunofluorescence on cells from a metastatic SLN is shown. BDCA2þ pDC coexpressed IDO
(yellow), although at a various degree of intensity. A subset of BDCA2/IDOþ large cells were also identified (indicated by asterisks). Inset, high magnification of
a BDCA2þ /IDOþ pDC. (b) Immunofluorescence on frozen section from a metastatic SLN is shown. The majority of BDCA2þ cells coexpressed IDO (yellow),
with only a few being IDO (indicated by arrows). Inset, high magnification of BDCA2þ /DOþ (yellow) and BDCA2þ /IDO (red) pDC. (c–d) Isotype controls for
anti-BDCA2 Ab (mouse IgG1) and anti-IDO Ab (rabbit IgG), in SLN and normal blood cytospins, respectively. No specific stainings were detected.
(e) Immunofluorescence on control LN and normal blood cytospins are shown. Control LN and blood BDCA2þ pDC did not express IDO (scale bars: a, b,
75mm and 30mm in the insets; c, d, 75 mm; e, 30mm).
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tumor-draining lymph nodes. These
cells prompt antigen-specific anergy,
strengthening the hypothesis that IDOþ
pDC are indeed tolerogenic (Munn
et al., 2004).
The existence and function of
human IDOþ pDC is as yet unknown.
This is probably because the antibodies
available against BDCA2 are not suita-
ble for paraffin-embedded archive
material. To understand whether IDOþ
DC correspond to pDC, we took
advantage of a recently described
method for phenotypic analysis of
cells from fresh and frozen human
SLN, which does not interfere with
pathological diagnosis (Vuylsteke et al.,
2002; Gerlini et al., 2007). The study
was conducted according to the De-
claration of Helsinki Principles, and
the Institutional Ethics Committee ap-
proved all described studies.
Samples were double stained with
mouse anti-human BDCA2 and rabbit
anti-human IDO. Variable numbers of
BDCA2þ pDC were found in all the
15 SLN analyzed by flow cytometry
(0.45±0.11%, mean±SD), and the
majority of them coexpressed IDO
(72.4±12.4 %), as assessed by immu-
nofluorescence (Figure 1a and b).
Notably, a subset of BDCA/IDOþ
large cells were also identified (Figure
1a). This finding suggests that other cells
express IDO in SLN. As pDC accumu-
late in metastatic SLN and typically
form clusters, frozen sections of meta-
static SLN were investigated. Numerous
BDCA2þ IDOþ pDC were observed,
with some IDO-negative pDC scattered
throughout the tissue (31.4±9.5%)
(Figure 1b). Functionally, BDCA2þ
pDC did not produce IFN-a (data not
shown, Gerlini et al., 2007). Impor-
tantly, control LN and blood pDC were
IDO negative (Figure 1e and see
Supplementary material for details),
suggesting that IDO expression may
be specific to tumor SLN.
The role of pDC in cancer immuno-
logy is still a matter of debate, as these
cells able to produce Type I IFN (Siegal
et al., 1999; Liu, 2001), as well as
promote tolerance (Munn et al., 2004;
Gerlini et al., 2007). By showing that
most of pDC express the immunosup-
pressive IDO in SLN of patients
with melanoma, our findings strongly
suggest that pDC have a tolerogenic
role in human cancer. Recently, human
pDC have been shown to upregulate
IDO in response to HIV infection
(Boasso et al., 2007). It is possible,
therefore, that metastatic melanoma
exploits this mechanism to repress
immune effector functions in SLN
(Cochran et al., 2006). Taken together,
these findings indicate that the identifi-
cation of IDOþ cells as the classical
BDCA2þ pDC of SLN is not only a
matter of immunophenotypic detail but
has remarkable immunopathological
and therapeutical significance.
Currently, different pharmacological
strategies have been adopted to cir-
cumvent tumor tolerance in SLN. Toll-
like receptor (TLR) agonists, such as the
TLR9 activator PF-3512676, promotes
DC-dependent proliferation of melano-
ma-specific CD8þ T cells as well as
effector natural killer cell responses
(Molenkamp et al., 2007, 2008). Simi-
larly, the TLR7 agonist imiquimod
reverts functional defect in pDC of
SLN, and boosts tumor-specific im-
mune responses in melanoma patients
(Molenkamp et al., 2007; Adams
et al., 2008). We claim that abrogating
the tolerogenic effects of IDO by means
of chemicals such as 1-methyl trypto-
phan (Hou et al., 2007) plus the
concomitant use of TLR7/9 agonists
might be an innovative pharmacologi-
cal strategy to revert tumor tolerance
in SLN.
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TO THE EDITOR
Non-melanoma skin cancer is the most
prevalent cancer in man. For reasons
that are unclear non-melanoma skin
cancer is dramatically increased in
organ transplant recipients (OTRs)
compared with immunocompetent pa-
tients (non-OTRs) (Euvrard et al., 2003).
Increased risk of metastasis and the
presence of multiple tumors are a
significant source of morbidity in OTRs.
These patients present with different
types of non-melanoma skin cancer
with squamous cell carcinoma (SCC)
and keratoacanthoma (KA) particularly
prevalent. The genetic aberrations
driving these cancers in OTRs and
non-OTRs are poorly understood.
Receptor tyrosine kinases are fre-
quently activated by somatic mutations
and/or amplification in human cancers,
particularly in epithelial tumors. To
determine whether receptor tyrosine
kinases are mutated in SCC, we
searched the literature to identify re-
ceptor tyrosine kinases that have a role
in epidermal homeostasis and thus
could be candidate oncogenes in squa-
mous lesions. We chose to analyze
epidermal growth factor receptor
(EGFR) that is highly expressed in a
small subset of metastatic cutaneous
SCCs (Bauknecht et al., 1985; Shimizu
et al., 2001; Maubec et al., 2005);
fibroblast growth factor receptor 3
(FGFR3) that is mutated in familial
acanthosis nigricans and Crouzon’s
syndrome, a type of craniosynostosis
(Berk et al., 2007) and induces acantho-
sis and benign tumors in transgenic
mice (Logie et al., 2005); and fibroblast
growth factor receptor 2 (FGFR2),
which is also mutated in Crouzon’s
syndrome and in this disease is asso-
ciated with acanthosis nigricans
(Meyers et al., 1995). We included the
insulin-like growth factor receptor 1
(IGF1R) mice lacking this receptor have
hypoplastic skin (Liu et al., 1993; De
Moerlooze et al., 2000) and MET, the
receptor for the ligand hepatocyte
growth factor. Mice overexpressing the
MET receptor exhibit an enhanced
number of hair follicles and accelerated
hair follicle morphogenesis (Lindner
et al., 2000), a feature associated with
cyclosporine use in OTRs. Finally, we
assessed ERBB2, which induces SCCs
when targeted to mouse skin (Kiguchi
et al., 2000).
We determined the mutation status
of the kinase domains of EGFR, IGF1R,
MET and ERBB2, and the regions of
FGFR2 and FGFR3 that are mutated in
Crouzon’s syndrome in a cohort of 95
tumors that consisted of 70 SCCs and
25 KAs from 55 OTR and 40 non-OTR
tumors; not every tumor was analyzed
for every gene. Genomic DNA was
extracted from archival formalin-fixed
paraffin-embedded samples and ampli-
fied with M13 sequence-tailed primers
(Supplementary Table 1).
Mutations were found in EGFR,
FGFR2, and FGFR3 but not in ERRB2,
MET, and IGF receptor 1 (Table 1). The
somatic nature of the mutations was
confirmed by sequencing the adjacent
normal skin in all three cases in which
mutations were found. EGFR was
mutated in 1 of 40 (2.5%) SCCs, a
frequency not dissimilar to that de-
tected in head and neck SCCs (7.3%)
(Willmore-Payne et al., 2006). The
particular Y727H mutation we found
in exon 18 of EGFR has been observed
in SCC of the lung (Pallis et al., 2007).
In addition to mutational activation,
amplification of wild-type EGFR can
drive tumorigenesis in a variety of
cancers and in head and neck SCC cell
lines (Weichselbaum et al., 1989). In a
dataset of array-based comparative
Abbreviations: FGFR, fibroblast growth factor receptor; KA, keratoacanthoma; OTR, organ transplant
recipient; RTK, receptor tyrosine kinase; SCC, squamous cell carcinoma
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